Latest News and Press Releases

Full Year 2024 Highlights Revenue increased 26% to €1,107 millionProfit for the period of €34 million was in-line with prior yearAdjusted EBITDA1 increased 33% to €222 million and Adjusted...

  Will Strengthen Company’s Global Offering for Most Bet Upon Sports Including Tennis, Soccer and Basketball      Expected to Accelerate Revenue, Adjusted EBITDA and Free Cash Flow Growth and...

Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects

BOSTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and...

HOCHIMINH CITY, Vietnam, March 13, 2025 (GLOBE NEWSWIRE) -- How can Resolution No. 57-NQ/TW of the Politburo serve as a catalyst for Vietnam’s semiconductor industry to master core technologies? This...

Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Ocular Hypertension - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The "Ocular Hypertension - Pipeline...

ST. GALLEN, Switzerland, March 06, 2025 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar”) will release its financial and operating results for the fourth quarter and full year...

NTHU & NHRI develop a new drug to treat chronic intestinal inflammation by blocking PANX1 channels, offering hope for IBD, published in Advanced Science.

Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025 Agreement by FDA to Initiate Second Global Phase 3...

– FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product...